Announced Fri, 11 Jul · 12:09 IST

Healthcare Global Enterprises Limited has informed the Exchange regarding letter of offer dated 10 July 2025 received by the Company from Kotak Mahindra Capital Company Limited, in relation to the Open Offer for the acquisition of Equity Shares from the Public Shareholders of the Company by Hector Asia Holdings II Pte. Ltd. (the Acquirer) together with Hector Asia Holdings I Pte. Ltd. (PAC 1), KKR Asia IV Fund Investments Pte. Ltd. (PAC 2) and KIA EBT II Scheme 1 (PAC 3 and together with PAC 1 and PAC 2, PACs), pursuant to and in compliance with the requirements of Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, as amended from time to time.'.

Listed Co AcquisitionOpen Offer TriggeredStrategic Transactions View source PDF

HCG · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve

Awaiting price reaction for this filing.

AI summary

Healthcare Global Enterprises (HCG) has informed the exchanges about receiving the Letter of Offer dated July 10, 2025 for a mandatory Open Offer under SEBI (SAST) Regulations. The acquirer, Hector Asia Holdings II Pte. Ltd. (Singapore), along with PACs including KKR Asia IV Fund Investments Pte. Ltd., is offering to buy up to 3.70 crore equity shares representing 26% of the expanded voting share capital from public shareholders at a price of INR 504.41 per share, translating to a maximum consideration of about INR 1,870.87 crores. The acquirer had already completed the first tranche purchase of 51% stake (7.19 crore shares) on May 30, 2025, which triggered this open offer. All required statutory approvals from the Competition Commission of India and the Competition Authority of Kenya have been received. The tendering period is scheduled from July 21, 2025 to August 1, 2025.

Likely market impact

Public shareholders have a clear exit window at INR 504.41 per share in cash, with the offer price acting as a near-term price reference for the stock. The mandatory nature of the offer, combined with KKR's backing, signals institutional validation of HCG's oncology business, though shares tendered above the offer size will be accepted on a proportionate basis.